• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND ARCHITECT AFP; ALPHA-FETOPROTEIN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND ARCHITECT AFP; ALPHA-FETOPROTEIN Back to Search Results
Catalog Number 03P36-35
Device Problem High Test Results (2457)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 11/08/2019
Event Type  malfunction  
Manufacturer Narrative
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.Section a patient information: no further information is available.Complete entry patient identifier: (b)(6).
 
Event Description
The customer reported a false elevated architect afp result for a (b)(6) female gastroenterology patient.Sample id (b)(6) generated an initial result of 1869.1 ng/ml and retest of 5.1 ng/ml.The patient also had a previous history of 5.2 ng/ml.No information on the patient's diagnosis or clinical presentation was available.No impact to patient management was reported.
 
Manufacturer Narrative
Investigation of the customers issue included a review of the complaint text, a search for similar complaints, in-house testing, review of field data, manufacturing documentation and labeling.Return testing was not completed as returns were not available.Review of complaint activity determined that there was normal complaint activity for reagent lot 96194fn00.Tracking and trending report review for the architect afp assay determined that there are no related trends.Using worldwide field data the historical performance of reagent lot 96194fn00 was evaluated and compared to the performance of all architect afp reagent lots in the field.This evaluation indicated that the patient median result for the lot was within 3sd of the established baseline.The reagent lot was further evaluated, an in-house retained kit of reagent lot 96194fn00 was used to test a panel of known concentration.All specifications were met indicating the lot was performing acceptably.Manufacturing documentation for the lot did not identify any issues.Labeling was reviewed and sufficiently addresses the customer's issue.No systemic issue or deficiency of the architect afp assay was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT AFP
Type of Device
ALPHA-FETOPROTEIN
Manufacturer (Section D)
ABBOTT IRELAND
diagnostics division
finisklin business park
sligo NA
EI  NA
MDR Report Key9363346
MDR Text Key219765109
Report Number3008344661-2019-00140
Device Sequence Number1
Product Code LOK
UDI-Device Identifier00380740112400
UDI-Public00380740112400
Combination Product (y/n)N
PMA/PMN Number
P120008
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 01/16/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/22/2019
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/31/2020
Device Catalogue Number03P36-35
Device Lot Number96184FN00
Was Device Available for Evaluation? No
Date Manufacturer Received01/14/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARCHITECT I2000SR, LIST 03M74-01,; ARCHITECT I2000SR, LIST 03M74-01,; SERIAL (B)(4); SERIAL (B)(4)
Patient Age69 YR
-
-